OCX

OncoCyte Corporation

3.03 USD

Last updated Dec 4, 20:09 UTC

Yesterday HIGH

$3.88

Yesterday LOW

$3.61

52w HIGH

$10

52w LOW

$2.08

EPS

-0.5

PE

-6.06

Next Earnings

Apr 3, 2023

Overview News Government Trades

OncoCyte Corporation stock is up 19.29% since 30 days ago. The next earnings date is Apr 3, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 December’s closed higher than November. 50% of analysts rate it a buy.

OncoCyte Corporation researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services.

Stock Exchange

NYSE MKT

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Alameda, United States Of America

Website

oncocyte.com

Benzinga Insights

Wed Aug 9, 2023

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 155 companies set new 52-week lows.
Benzinga Newsdesk

Wed Aug 9, 2023

Oncocyte Regains Compliance With Nasdaq Listing Requirements
Benzinga Insights

Tue Aug 8, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's trading, 188 companies set new 52-week lows.
Happy Mohamed

Mon Jul 24, 2023

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Corporation (NASDAQ:OCX) (the "Company"), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common
Happy Mohamed

Tue Jun 27, 2023

Oncocyte Begins Manufacturing Transplant Blood Test

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics
Benzinga Insights

Thu May 11, 2023

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
Benzinga Newsdesk

Thu May 11, 2023

OncoCyte Q1 EPS $0.02 Vs. $(0.11) Prior Year, Sales $297.00K Miss $350.00K Estimate

OncoCyte (NASDAQ:OCX) reported quarterly earnings of $0.02 per share versus losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $297.00 thousand which missed the analyst
Vandana Singh

Thu Apr 13, 2023

Oncocyte's Announces Another Round Of Layoffs Leaving 20% Of Staff Impacted
Happy Mohamed

Thu Apr 13, 2023

Reported Late Wednesday April 12, Oncocyte Corporation Announces A Reduction In Force Involving ~20% Of Its Workforce, Which Management Believes Will Extend Oncocyte's Cash Runway In 2024

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte's
Lisa Levin

Mon Apr 10, 2023

$2M Bet On Cocrystal Pharma? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Piper Sandler

Mon Nov 13, 16:18

hold

confirm
Needham

Thu Nov 9, 11:42

buy

confirm